Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

SGLT2 Inhibitors in Diabetes Mellitus Treatment.

Rosas-Guzmán J, Rosas-Saucedo J, Romero-García AR.

Rev Recent Clin Trials. 2016 Aug 29. [Epub ahead of print]

PMID:
27765008
2.

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.

Simó R, Guerci B, Schernthaner G, Gallwitz B, Rosas-Guzmàn J, Dotta F, Festa A, Zhou M, Kiljański J.

Cardiovasc Diabetol. 2015 Sep 4;14:116. doi: 10.1186/s12933-015-0279-z.

3.

Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.

Schernthaner G, Rosas-Guzmán J, Dotta F, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B.

Diabetes Obes Metab. 2015 Jul;17(7):689-98. doi: 10.1111/dom.12471. Epub 2015 May 8.

PMID:
25846577
4.

Low-molecular-weight heparin and mortality in acutely ill medical patients.

Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators..

N Engl J Med. 2011 Dec 29;365(26):2463-72. doi: 10.1056/NEJMoa1111288.

5.

Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association.

Guzmán JR, Lyra R, Aguilar-Salinas CA, Cavalcanti S, Escaño F, Tambasia M, Duarte E; ALAD Consensus Group..

Rev Panam Salud Publica. 2010 Dec;28(6):463-71.

6.

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.

Liutkus J, Rosas Guzman J, Norwood P, Pop L, Northrup J, Cao D, Trautmann M.

Diabetes Obes Metab. 2010 Dec;12(12):1058-65. doi: 10.1111/j.1463-1326.2010.01251.x.

PMID:
20977576
7.

Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America.

Lopez Stewart G, Tambascia M, Rosas Guzmán J, Etchegoyen F, Ortega Carrión J, Artemenko S.

Rev Panam Salud Publica. 2007 Jul;22(1):12-20.

PMID:
17931483
8.

Normokalemic thyrotoxic periodic paralysis: a new therapeutic strategy.

González-Treviño O, Rosas-Guzmán J.

Thyroid. 1999 Jan;9(1):61-3.

PMID:
10037078
9.

[Diffuse toxic goiter treated with 131I. 30 years' experience].

Rosas Guzmán J, González Treviño O, Luviano Vázquez C, Maisterrena J.

Rev Invest Clin. 1987 Jan-Mar;39(1):11-8. Spanish. No abstract available.

PMID:
3602662

Supplemental Content

Loading ...
Support Center